Connect Biopharma Holdings Ltd
CNTB2.400USD
+0.130+5.73%
交易中 （美东）报价延迟15分钟
133.89M总市值
亏损市盈率 TTM
关于 Connect Biopharma Holdings Ltd 公司
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Connect Biopharma Holdings Ltd简介
公司代码CNTB
公司名称Connect Biopharma Holdings Ltd
上市日期Mar 19, 2021
CEOQuart (Barry D)
员工数量62
证券类型Ordinary Share
年结日Mar 19
公司地址3580 Carmel Mountain Road, Suite 200
城市SAN DIEGO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92130
电话18587271040
网址https://www.connectbiopharm.com
公司代码CNTB
上市日期Mar 19, 2021
CEOQuart (Barry D)
Connect Biopharma Holdings Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
131.89K
--
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
80.00K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Dr. Lei Sun, Ph.D.
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
--
--
Mr. Jeff Cohn, J.D.
Mr. Jeff Cohn, J.D.
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Raul Collazo, Ph.D.
Mr. Raul Collazo, Ph.D.
Vice President - Global Medical Affairs
Vice President - Global Medical Affairs
--
--
Mr. David L. Szekeres
Mr. David L. Szekeres
President
President
--
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
131.89K
--
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
80.00K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Dr. Lei Sun, Ph.D.
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Panacea Venture
21.47%
BioFortune Inc
11.02%
Shanghai Minhui Enterprise Management Consulting Partnership
9.49%
Wei (Zheng)
9.35%
Qiming Venture Partners
8.66%
其他
40.02%
持股股东
持股股东
占比
Panacea Venture
21.47%
BioFortune Inc
11.02%
Shanghai Minhui Enterprise Management Consulting Partnership
9.49%
Wei (Zheng)
9.35%
Qiming Venture Partners
8.66%
其他
40.02%
股东类型
持股股东
占比
Venture Capital
36.14%
Corporation
29.03%
Individual Investor
10.12%
Investment Advisor
2.57%
Hedge Fund
0.28%
Investment Advisor/Hedge Fund
0.15%
其他
21.72%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
39
23.82M
44.06%
--
2025Q3
44
23.82M
51.87%
-292.56K
2025Q2
43
24.11M
49.99%
-302.92K
2025Q1
42
24.43M
50.72%
-3.65M
2024Q4
48
24.78M
51.96%
+236.30K
2024Q3
55
24.55M
53.49%
-34.12K
2024Q2
62
24.58M
57.85%
+441.50K
2024Q1
65
24.14M
48.89%
-2.80M
2023Q4
72
21.31M
33.82%
+215.31K
2023Q3
80
21.09M
40.53%
-286.24K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Panacea Venture
13.95M
25.04%
+540.00K
+4.03%
Jul 21, 2025
BioFortune Inc
6.16M
11.05%
--
--
Mar 21, 2025
Shanghai Minhui Enterprise Management Consulting Partnership
5.31M
9.52%
--
--
Mar 21, 2025
Wei (Zheng)
5.93M
10.64%
--
--
Mar 21, 2025
Qiming Venture Partners
4.84M
8.69%
--
--
Mar 21, 2025
Advantech Capital II L.P.
4.76M
8.55%
--
--
Mar 21, 2025
Lilly Asia Ventures
3.34M
5.99%
--
--
Mar 21, 2025
BML Capital Management LLC
1.82M
3.27%
-271.67K
-12.98%
Jun 30, 2025
Szekeres (David Leslie)
160.87K
0.29%
+160.87K
--
Mar 21, 2025
Renaissance Technologies LLC
143.70K
0.26%
+28.90K
+25.17%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
SPDR Portfolio Emerging Markets ETF
0%
SPDR Portfolio Emerging Markets ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Connect Biopharma Holdings Ltd的前五大股东是谁？
Connect Biopharma Holdings Ltd 的前五大股东如下：
Panacea Venture持有股份：13.95M，占总股份比例：25.04%。
BioFortune Inc持有股份：6.16M，占总股份比例：11.05%。
Shanghai Minhui Enterprise Management Consulting Partnership持有股份：5.31M，占总股份比例：9.52%。
Wei (Zheng)持有股份：5.93M，占总股份比例：10.64%。
Qiming Venture Partners持有股份：4.84M，占总股份比例：8.69%。
Panacea Venture持有股份：13.95M，占总股份比例：25.04%。
BioFortune Inc持有股份：6.16M，占总股份比例：11.05%。
Shanghai Minhui Enterprise Management Consulting Partnership持有股份：5.31M，占总股份比例：9.52%。
Wei (Zheng)持有股份：5.93M，占总股份比例：10.64%。
Qiming Venture Partners持有股份：4.84M，占总股份比例：8.69%。
Connect Biopharma Holdings Ltd的前三大股东类型是什么？
Connect Biopharma Holdings Ltd 的前三大股东类型分别是：
Panacea Venture
BioFortune Inc
Shanghai Minhui Enterprise Management Consulting Partnership
Panacea Venture
BioFortune Inc
Shanghai Minhui Enterprise Management Consulting Partnership
有多少机构持有Connect Biopharma Holdings Ltd(CNTB)的股份？
截至2025Q4，共有39家机构持有Connect Biopharma Holdings Ltd的股份，合计持有的股份价值约为23.82M，占公司总股份的44.06%。与2025Q3相比，机构持股有所增加，增幅为-7.81%。
哪个业务部门对Connect Biopharma Holdings Ltd的收入贡献最大？
在--，--业务部门对Connect Biopharma Holdings Ltd的收入贡献最大，创收--，占总收入的--%。
